Salarius Pharmaceuticals Inc SLRX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 9:34 AM EDT
0.50quote price arrow up+0.0055 (+1.1122%)
Volume
8,986
52 week range
0.43 - 1.87
Loading...
  • Open0.50
  • Day High0.5002
  • Day Low0.50
  • Prev Close0.4945
  • 52 Week High1.87
  • 52 Week High Date06/08/23
  • 52 Week Low0.43
  • 52 Week Low Date04/02/24

Key Stats

  • Market Cap2.388M
  • Shares Out4.78M
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta1.04
  • YTD % Change-23.06

KEY STATS

  • Open0.50
  • Day High0.5002
  • Day Low0.50
  • Prev Close0.4945
  • 52 Week High1.87
  • 52 Week High Date06/08/23
  • 52 Week Low0.43
  • 52 Week Low Date04/02/24
  • Market Cap2.388M
  • Shares Out4.78M
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta1.04
  • YTD % Change-23.06

RATIOS/PROFITABILITY

  • EPS (TTM)-4.54
  • P/E (TTM)-0.11
  • Fwd P/E (NTM)-0.02
  • EBITDA (TTM)-12.885M
  • ROE (TTM)-160.07%
  • Revenue (TTM)-
  • Gross Margin (TTM)1.66%
  • Net Margin (TTM)-2,979.68%
  • Debt To Equity (MRQ)5.48%

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Salarius Pharmaceuticals Inc

 

Content From Our Affiliates

Profile

MORE
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule...
William McVicar Ph.D.
Non-Executive Chairman of the Board
David Arthur
President, Chief Executive Officer, Director
Mark Rosenblum CPA
Chief Financial Officer, Executive Vice President - Finance
Address
2450 Holcombe Blvd Ste J-608
Houston, TX
77021-2041
United States

Top Peers

SYMBOLLASTCHG%CHG
DRMA
Dermata Therapeutics Inc
4.10-0.10-2.38%
GLMD
Galmed Pharmaceuticals Ltd
0.392-0.013-3.2099%
MBIO
Mustang Bio Inc
0.3197+0.0077+2.4679%
REVB
Revelation Biosciences Inc
2.00-0.02-0.99%
BBLG
Bone Biologics Corp
1.87-0.01-0.53%